Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $4.2852W HIGH $31.35
Volume
2.85 M
Value Traded
12.59 M
Short % Float
6.6%
+1.75%Week
-28.88%1 Month
-75.38%3 Month
-69.76%6 Month
+63.11%5 Year
+63.11%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
902.16 M
EPS (TTM)
-3.39
P/E Ratio
-
Ent. Value
399.87 M
Total Shares
129.44 M
Float Shares
95.39 M
Insiders
28.54%
Institutions
67.41%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
ALMS Catalyst Timeline
Dated clinical, regulatory and corporate events for Alumis Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Alumis Inc.
136Total events
9Upcoming
38Tier-1 (high impact)
2023 to 2027Coverage
Upcoming catalysts 2
Event history 50
▼Topline ReadoutEnvudeucitinibClinical Data
LUMUS trial topline results announced
systemic lupus erythematosussource ↗
▼Primary Endpoint MissedEnvudeucitinibClinical Data
LUMUS trial missed primary endpoint in overall population
systemic lupus erythematosussource ↗
▲Subgroup AnalysisEnvudeucitinibClinical Data
Prespecified IFNGS-high subgroup showed robust responses
systemic lupus erythematosussource ↗
▲Safety Data UpdateEnvudeucitinibClinical Data
Envudeucitinib well tolerated with no new safety signals
systemic lupus erythematosussource ↗
▲PK PD DataEnvudeucitinibClinical Data
Dose-dependent interferon-pathway target engagement observed
systemic lupus erythematosussource ↗
●Oral PresentationEnvudeucitinibPresentation
Conference call and webcast to review LUMUS results
systemic lupus erythematosussource ↗
▲Topline ReadoutEnvudeucitinibClinical Data
ONWARD3 long-term extension topline results: 75% PASI 90 and 54% PASI 100 at 48 weeks
moderate-to-severe plaque psoriasissource ↗
▼Program DiscontinuationlonigutamabDiscontinuedCorporate
Strategic review of lonigutamab program completed; exploring strategic alternatives
●Pipeline PrioritizationEnvudeucitinibCorporate
Prioritization of Sjögren's disease and CLE as next indications for envudeucitinib
Sjögren's disease and cutaneous lupus erythematosussource ↗
▲Full ResultsEnvudeucitinibClinical Data
ONWARD3 48-week data show 54% PASI 100
plaque psoriasissource ↗
◆Topline ReadoutEnvudeucitinibClinical Data
Potentially pivotal Phase 2b LUMUS topline data in SLE
systemic lupus erythematosussource ↗
◆Topline ReadoutESK-001Clinical Data
Topline data expected from LUMUS Phase 2b trial of ESK-001 for SLE
systemic lupus erythematosussource ↗
●Timing GuidanceEnvudeucitinibPresentation
Planned NDA submission to FDA for envudeucitinib in plaque psoriasis
moderate-to-severe plaque psoriasissource ↗
◆Pipeline PrioritizationCorporate
Plan to announce TYK2 franchise development strategy for additional indications
◆R&D DayEnvudeucitinibPresentation
Investor webcast to review Phase 3 ONWARD data
moderate-to-severe plaque psoriasissource ↗
◆Late-BreakerEnvudeucitinibPresentation
Late-breaking oral presentation of 24-week results from Phase 3 ONWARD1 and ONWARD2 studies at AAD 2026
moderate-to-severe plaque psoriasissource ↗
◆Poster PresentationEnvudeucitinibPresentation
E-poster presentation of biomarker analysis from Phase 2 STRIDE trial at AAD 2026
moderate-to-severe plaque psoriasissource ↗
▲Oral PresentationEnvudeucitinibPresentation
Late-breaking oral presentation of Phase 3 ONWARD1 and ONWARD2 data at AAD 2026
moderate-to-severe plaque psoriasissource ↗
▲Topline ReadoutEnvudeucitinibClinical Data
Topline data from Phase 3 ONWARD1 and ONWARD2 trials
moderate-to-severe plaque psoriasissource ↗
▲Primary Endpoint MetEnvudeucitinibClinical Data
Co-primary endpoints met in ONWARD1 and ONWARD2
moderate-to-severe plaque psoriasissource ↗
▲Full ResultsEnvudeucitinibClinical Data
Phase 3 ONWARD1 and ONWARD2 topline results presented at AAD
moderate-to-severe plaque psoriasissource ↗
▲Topline ReadoutEnvudeucitinibClinical Data
Positive Phase 3 topline results for envudeucitinib in PsO
moderate-to-severe plaque psoriasissource ↗
◆Oral PresentationPresentation
Alumis to present at Leerink Partners Global Healthcare Conference
▲Oral PresentationEnvudeucitinibPresentation
Late-breaking oral presentation of Phase 3 envudeucitinib data at 2026 AAD Annual Meeting
moderate-to-severe plaque psoriasissource ↗
▼Equity OfferingCorporate
Closing of upsized public offering of 20,297,500 shares at $17.00 per share, gross proceeds $345.1 million
▼Equity OfferingCorporate
Pricing of upsized underwritten public offering of 17,650,000 shares at $17.00 per share
◆Topline ReadoutEnvudeucitinibClinical Data
Topline data from Phase 3 ONWARD program for envudeucitinib in plaque psoriasis
moderate-to-severe plaque psoriasissource ↗
◆Oral PresentationEnvudeucitinibPresentation
Conference call and webcast to discuss Phase 3 ONWARD topline data
moderate-to-severe plaque psoriasissource ↗
▲Primary Endpoint MetEnvudeucitinibClinical Data
ONWARD1 met all primary and secondary endpoints with high statistical significance
moderate-to-severe plaque psoriasissource ↗
◆Topline ReadoutEnvudeucitinibClinical Data
Topline readout expected in early Q1 2026 for envudeucitinib in plaque psoriasis
moderate-to-severe plaque psoriasissource ↗
◆Topline ReadoutESK-001Clinical Data
Topline results expected from ONWARD1 Phase 3 trial of ESK-001
moderate-to-severe plaque psoriasissource ↗
◆Oral PresentationPresentation
Stifel 2025 Virtual Immunology & Inflammation Forum virtual presentation
◆Oral PresentationPresentation
H.C. Wainwright 27th Annual Global Investment Conference presentation
◆Oral PresentationPresentation
Morgan Stanley 23rd Annual Global Healthcare Conference fireside chat
▲Enrollment CompleteEnvudeucitinibTrial
Completed enrollment in Phase 3 ONWARD clinical trials for envudeucitinib in moderate-to-severe plaque psoriasis
moderate-to-severe plaque psoriasissource ↗
▲Runway Guidance UpdateCorporate
Cash runway guidance: $486.3M expected to fund operations into 2027
▲Enrollment CompleteESK-001Trial
Completed patient enrollment in global LUMUS Phase 2b trial of ESK-001 for SLE
systemic lupus erythematosussource ↗
Past FDA Catalysts and PDUFA Decisions
How ALMS actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-09-30 | ESK-001 (next-generation oral TYK2 inhibitor) | Phase 2b data readout | Phase 2b |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
C53 / 100
Pipeline Score
$966M
Pipeline Value
Fair Value
Valuation Signal
4
Drugs Scored
1.1x
rNPV / MCap
Top 13%
Micro Cap(rank 86 of 658)
Percentile Rank
Alumis Inc. carries a moderate pipeline score (53/100), with $2.7B risk-adjusted pipeline value, led by Envudeucitinib in Plaque Psoriasis (Phase 3), across $85B in total addressable markets.
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Envudeucitinib Small moleculeNCT05739435 | Plaque Psoriasis | Phase 3 | ACTIVE NOT_RECRUITING | 3,619 | Dec 31, 2027 |
Clinical Trial Results
Readouts, endpoints and source filings for every ALMS program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| envudeucitinib | systemic lupus erythematosus | Phase 2b | 2026-09-01 | did not meet its primary and secondary endpoints in the overall trial population; Robust clinical responses were observed in a prespecified subgroup analysis of patients with high interferon gene signature (IFNGS-high); IFNGS-high patients were unexpectedly under-represented, reducing response rates in the overall trial populationRead More | Alumis Announces Topline Results from Envudeucitinib Phase 2b Trial in Systemic Lupus Erythematosus (SLE)Read More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| AKKARAJU SRINIVASDirector | Sell | -48,066 4,663,735 held | $10.55 | 09/08/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in ALMS
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| Deep Track Capital, LP | 2.6 % (8.3 %) | 178.65 M | 6.35 M | -6.26% ( -424.04 K) |
ALMS Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How ALMS ranks across every disease it competes in
Competitive Position is a premium feature
See how ALMS ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialALMS News
ALMSAlumis to Participate in Upcoming September Investor Conferences
Alumis Inc. will participate in several investor conferences in September 2026, including the Wells Fargo and Cantor Global Healthcare Conferences. The company focuses on developing targeted therapies for immune-mediated diseases, leveraging a proprietary data analytics platform. Their pipeline includes envudeucitinib for systemic disorders and A-005 for neuroinflammatory conditions.
Read more →ALMS▼ -56.6%on this news
Alumis Announces Topline Results from Envudeucitinib Phase 2b Trial in Systemic Lupus Erythematosus (SLE)
Alumis announced that its Phase 2b LUMUS trial for envudeucitinib in systemic lupus erythematosus did not meet its primary and secondary endpoints. However, significant responses were noted in a subgroup of patients with a high interferon gene signature, supporting further development. The drug was well tolerated, and Alumis plans to engage with regulators for Phase 3 development.
Read more →ALMSAlumis Reports Second Quarter 2026 Financial Results and Highlights Recent Achievements
Alumis Inc. reported its Q2 2026 financial results, highlighting significant achievements in its clinical trials for envudeucitinib, a TYK2 inhibitor. The company noted a 54% complete skin clearance rate in psoriasis patients and is on schedule to submit a New Drug Application to the FDA by Q4 2026. Additionally, pivotal data for systemic lupus erythematosus is expected in Q3 2026, with plans to advance further indications.
Read more →ALMS▼ -7.8%on this newsshared move
Envudeucitinib Long-term Data Positioned to Set a New Standard for Plaque Psoriasis Treatment, Delivering Highest Reported PASI 100 Skin Clearance Among Oral Therapies
The ONWARD3 data indicates that 54% of patients treated with envudeucitinib achieved complete skin clearance after 48 weeks. The treatment demonstrated a favorable long-term safety and tolerability profile consistent with earlier findings. The company is preparing to submit a New Drug Application to the FDA in the fourth quarter.
Read more →ALMSAlumis Reports First Quarter 2026 Financial Results and Highlights Recent Achievements
Alumis Inc. reported its financial results for Q1 2026 and highlighted key developments in the clinical performance of envudeucitinib, a novel treatment for moderate-to-severe plaque psoriasis. Phase 3 trial data presented at the American Academy of Dermatology Annual Meeting demonstrated significant improvements in skin clearance and patient-reported quality-of-life measures. The company plans to submit a New Drug Application (NDA) for envudeucitinib in Q4 2026 and anticipates pivotal data for treating systemic lupus erythematosus in Q3 2026. Overall, the results reinforce Alumis' confidence in envudeucitinib's ability to reshape psoriasis therapy.
Read more →ALMS▼ -18.5%on this news
Alumis’ Envudeucitinib Delivers Early and Robust Improvements in Skin Clearance, Quality of Life and Psoriasis Symptoms in Two Phase 3 Trials, Underscoring Its Potential as a Leading Oral Therapy for Plaque Psoriasis
Alumis Inc. announced promising results from its Phase 3 ONWARD1 and ONWARD2 trials for envudeucitinib, a selective TYK2 inhibitor for moderate-to-severe plaque psoriasis. The trials demonstrated significant skin clearance and improvements in quality of life, with a favorable safety profile. The company plans to submit a New Drug Application to the FDA later this year.
Read more →ALMSAlumis Reports Year End 2025 Financial Results and Highlights Recent Achievements
Alumis Inc. reported strong financial results for 2025, highlighting successful Phase 3 trials for envudeucitinib in moderate-to-severe plaque psoriasis. The drug demonstrated significant skin clearance and symptom improvement, with a favorable safety profile. Alumis plans to submit a New Drug Application (NDA) for envudeucitinib in the second half of 2026 and anticipates pivotal data for systemic lupus erythematosus in Q3 2026.
Read more →ALMSAlumis Announces Late-Breaker Oral Presentation of Phase 3 Data for Envudeucitinib in Moderate-to-Severe Plaque Psoriasis at 2026 American Academy of Dermatology Annual Meeting
Alumis Inc. has announced that the results from its Phase 3 ONWARD clinical trials evaluating envudeucitinib for moderate-to-severe plaque psoriasis will be presented orally at the 2026 American Academy of Dermatology Annual Meeting. Additionally, a biomarker analysis from the Phase 2 STRIDE trial will be showcased as an e-poster. The presentations are set for March 28, 2026, with a follow-up investor webcast scheduled the following day to review the ONWARD trial data. Envudeucitinib, a next-generation TYK2 inhibitor, is also under evaluation for other immune-mediated diseases.
Read more →ALMSAlumis to Present at the Leerink Partners Global Healthcare Conference
Alumis Inc. will present at the Leerink Partners Global Healthcare Conference on March 9, 2026. CEO Martin Babler will participate in a fireside chat, which will be available via live webcast. The company focuses on developing targeted therapies for immune-mediated diseases, including oral tyrosine kinase 2 inhibitors and other innovative treatments.
Read more →ALMSAlumis to Participate in Upcoming February Investor Conferences
Alumis Inc. has announced its participation in several upcoming investor conferences. The company, known for developing next-generation targeted therapies for immune-mediated diseases, aims to enhance patient health outcomes. Their pipeline includes oral tyrosine kinase 2 inhibitors and other innovative treatments. Webcast replays will be available on their website for 90 days.
Read more →ALMS▲ +7.6%on this news· ran to +34% by day 3
Alumis Announces Closing of Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
Alumis Inc. has successfully closed an upsized public offering of 20,297,500 shares of common stock, raising approximately $345.1 million. The offering included the full exercise of the underwriters' option to purchase an additional 2,647,500 shares at a price of $17.00 per share. The offering was conducted under a previously filed shelf registration statement and managed by several financial institutions. Alumis is focused on developing targeted therapies for immune-mediated diseases, leveraging a proprietary data analytics platform and a promising pipeline.
Read more →ALMSAlumis Announces Pricing of Upsized Public Offering of Common Stock
Alumis Inc. has announced the pricing of an upsized public offering of 17,650,000 shares of its common stock at a price of $17.00 per share, totaling approximately $300 million in gross proceeds. The offering is expected to close on January 9, 2026, barring any unforeseen circumstances. Alumis has also granted underwriters a 30-day option to purchase additional shares. This move underscores the company's efforts to fund the development of its innovative therapies for immune-mediated diseases.
Read more →ALMS▲ +95.3%on this newsshared move
Alumis to Host Conference Call and Webcast to Report Phase 3 ONWARD Topline Data for Envudeucitinib in Moderate-to-Severe Plaque Psoriasis
Alumis Inc. will announce topline data from its Phase 3 ONWARD clinical program for envudeucitinib, targeting moderate-to-severe plaque psoriasis, on January 6, 2026. A conference call and webcast will follow to discuss the results. The company aims to improve patient outcomes with its next-generation therapies.
Read more →ALMS▲ +95.3%on this newsshared move
Alumis Announces Proposed Public Offering of Common Stock
Alumis Inc. has announced a proposed underwritten public offering of $175 million worth of common stock, with an additional option for underwriters to purchase another $26.25 million in shares. The offering aims to fund the development of its pipeline of targeted therapies for immune-mediated diseases. The company has filed a registration statement with the SEC for the offering, which remains subject to market conditions and uncertainties regarding completion.
Read more →ALMS▲ +95.3%on this newsshared move
Alumis' Envudeucitinib Delivers Leading Skin Clearance Among Next-Generation Oral Plaque Psoriasis Therapies in Phase 3 Program
Alumis Inc. announced positive topline results from its Phase 3 ONWARD1 and ONWARD2 clinical trials for envudeucitinib, a selective TYK2 inhibitor for moderate-to-severe plaque psoriasis. The trials demonstrated high statistical significance in achieving primary endpoints, with notable skin clearance in patients. Approximately 65% of participants achieved PASI 90 at Week 24. Envudeucitinib is expected to transform oral psoriasis therapy and Alumis plans to submit a New Drug Application to the FDA in 2026.
Read more →ALMSAlumis Reports Third Quarter 2025 Financial Results and Highlights Recent Progress
Alumis Inc. reported its financial results for Q3 2025, highlighting both its financial challenges and significant upcoming milestones in drug development. The company anticipates key data from its Phase 3 ONWARD trial for envudeucitinib in moderate-to-severe plaque psoriasis in early 2026 and from its Phase 2b LUMUS study in systemic lupus erythematosus later in the year. Despite facing a net loss of $110,752 for the quarter, Alumis remains optimistic about its robust pipeline and potential market opportunities for its drugs.
Read more →ALMSAlumis to Participate in Upcoming November Investor Conferences
Alumis Inc. has announced its participation in several upcoming investor conferences in November. The company focuses on developing next-generation targeted therapies for immune-mediated diseases, including oral tyrosine kinase inhibitors and other innovative treatments. Their participation highlights their commitment to engaging with investors and showcasing their advancements in biopharma.
Read more →ALMSTransform Therapies. Reimagine Lives. September 2025 Corporate Presentation 2© Alumis Forward-Looking Statements This presentation contains forward looking statements within the meaning of federal securities laws, i
Alumis is advancing its clinical pipeline with several near-term milestones expected, including the initiation of Phase 2 trials for its A-005 candidate in multiple sclerosis. The company also focuses on Lonigutamab, which targets IGF-1R and has been shown to potentially have a differentiated safety profile, critical to addressing significant unmet needs in thyroid eye disease (TED). Additionally, Alumis plans to speed up its ongoing Phase 2b program for systemic lupus erythematosus (SLE) while aiming for accelerated regulatory pathways. A positive initial response in clinical trials bolsters the strategic focus on not only immediate therapies but also future-market potential.
Read more →About Alumis Inc.
Headquarters280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO, CA, 94080
BIOPHARMAWATCH ELITE PLUS
Trade the next ALMS catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime